How many employees work at Lotus Pharmaceutical?

About Lotus Pharmaceutical

Lamex Chemical Pharmaceuticals Co., Ltd. (stock code) was established in 2006 and is currently the largest pharmaceutical company in Taiwan by revenue and a global pharmaceutical company. Lamex focuses on the commercialization of new drugs and generic drugs, and is committed to providing patients with better, safer and more accessible drugs. The company has a first-class R&D and manufacturing platform recognized in Asia and has established partnerships in almost all global markets, including the United States, Europe, Japan, China and Brazil. Lamex has more than a number of strategically selected pharmaceutical projects underway in Asia and the United States, including multiple commercialized products. Through internal R&D investment and cooperation licensing, the company invests in high-barrier oncology drugs, complex generic drugs, and a diversified best product portfolio composed of (b) and NCE, and strengthens biosimilar drug products with the support of strategic partners to Strengthen the competitiveness of its product portfolio. Lamex has the top R&D centers and production equipment in Asia. It is also the only pharmaceutical factory in Taiwan that has obtained certification from the US FDA, EU EMA, Japanese PDMA, Chinese FDA, and Brazilian ANVISA. Founded in , Lotus: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S, Europe, Japan, China, and Brazil. Lotus runs over strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over commercial products. The Company invests in diversified best The portfolio consists of high-barrier oncology, complex generics as well as (b) and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.